Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



Maggie McConnell's Articles

Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology

Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into an exclusive agreement to co-develop a new, ready-to-use injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc.

Arecor announces positive headline results for the first Phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.  In the study, AT247 provided a favourable pharmacokinetic/pharmacodynamic profile compared with NovoRapid® and Fiasp®.

Arecor to present at the Sixth China Healthcare Summit 2019 in Shanghai, China

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that its Chief Executive Officer, Dr Sarah Howell, will present at The sixth China Healthcare Summit, held from 18th to 20th November at the Jing An Shangri-La, Shanghai, China.

Arecor appoints Jim Macdonald-Clink As Vice President, Business Development

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Jim MacDonald-Clink as Vice President, Business Development with immediate effect. 

Arecor and JDRF sign a joint research, development and commercialisation agreement to develop a co-formulation insulin for the treatment of diabetes

Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research.

Arecor: Dosing Complete In Phase I Clinical Trial Of Ultra-Rapid Acting Insulin Product Candidate AT247 For Diabetes

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247

Arecor Welcomes Discussion With Mrs Kemi Badenoch, MP For Saffron Walden

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, welcomed Mrs Kemi Badenoch, MP for Saffron Walden, to its offices at Chesterford Research Park.

Arecor: Signs A New Formulation Evaluation Agreement With An Existing Partner, A Major Global Pharmaceutical Company

Arecor Limited, the specialty pharmaceutical company, leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.

Arecor receives regulatory approval to initiate phase I clinical trial for ultra-rapid acting insulin product

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.

Arecor appoints Chief Financial Officer

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect from 4th March 2019.

Pages: Previous12NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

https://0123movie.net